Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Author S Id	Title	Year	Source Title	Volume	Issue	Art No	Page Start	Page End	Cited By	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Publisher	Issn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 92 of 93 Start Prev 84 85 86 87 88 89 90 91 92 93 Next End
53(1)
No records
548	Pranata R., Henrina J., Lim M.A., Lawrensia S., Yonas E., Vania R., Huang I., Lukito A.A., Suastika K., Kuswardhani R.A.T., Setiati S.	57201973901;57218482646;57216039756;57219781613;57201987097;57208328436;57208576645;57213835420;8736266500;36863900500;14325991900;	Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis: Clinical Frailty Scale in COVID-19	2021	Archives of Gerontology and Geriatrics	93		104324			53	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098467342&doi=10.1016%2fj.archger.2020.104324&partnerID=40&md5=f9eef93f03ae5cb88ddf255820cbd190	Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Siloam Heart Institute, Jakarta, Indonesia; Ken Saras General Hospital, Semarang, Indonesia; Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Division of Plastic, Reconstructive and Aesthetic, Department of Surgery, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Udayana University Denpasar, Bali, Indonesia; Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Denpasar - Bali, Indonesia; Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo General Hospital, Jakarta, Indonesia	Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Henrina, J., Siloam Heart Institute, Jakarta, Indonesia; Lim, M.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Lawrensia, S., Ken Saras General Hospital, Semarang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Vania, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia, Division of Plastic, Reconstructive and Aesthetic, Department of Surgery, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali, Indonesia; Huang, I., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Lukito, A.A., Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia; Suastika, K., Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Udayana University Denpasar, Bali, Indonesia; Kuswardhani, R.A.T., Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Denpasar - Bali, Indonesia; Setiati, S., Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo General Hospital, Jakarta, Indonesia	Introduction: National Institute for Health and Care Excellence (NICE) endorsed clinical frailty scale (CFS) to help with decision-making. However, this recommendation lacks an evidence basis and is controversial. This meta-analysis aims to quantify the dose-response relationship between CFS and mortality in COVID-19 patients, with a goal of supplementing the evidence of its use. Methods: We performed a systematic literature search from several electronic databases up until 8 September 2020. We searched for studies investigating COVID-19 patients and reported both (1) CFS and its distribution (2) CFS and its association with mortality. The outcome of interest was mortality, defined as clinically validated death or non-survivor. The odds ratio (ORs) will be reported per 1% increase in CFS. The potential for a non-linear relationship based on ORs of each quantitative CFS was examined using restricted cubic splines with a three-knots model. Results: There were a total of 3817 patients from seven studies. Mean age was 80.3 (SD 8.2), and 53% (48–58%) were males. The pooled prevalence for CFS 1–3 was 34% (32–36%), CFS 4–6 was 42% (40–45%), and CFS 7–9 was 23% (21–25%). Each 1-point increase in CFS was associated with 12% increase in mortality (OR 1.12 (1.04, 1.20), p = 0.003; I2: 77.3%). The dose-response relationship was linear (Pnon-linearity=0.116). The funnel-plot analysis was asymmetrical; Trim-and-fill analysis by the imputation of two studies on the left side resulted in OR of 1.10 [1.03, 1.19]. Conclusion: This meta-analysis showed that increase in CFS was associated with increase in mortality in a linear fashion. © 2020 Elsevier B.V.	Age; Coronavirus; COVID-19; Frailty; Prognosis; Risk stratification	Article; Clinical Frailty Scale; coronavirus disease 2019; data analysis; functional status assessment; human; medical research; mortality; odds ratio; outcome assessment; prevalence; priority journal; quantitative analysis; systematic error; systematic review; frailty; male; meta analysis; very elderly; Aged, 80 and over; COVID-19; Frailty; Humans; Male; Prevalence; SARS-CoV-2	Elsevier Ireland Ltd	01674943	33352430	Article	Q1	985	4466	View
6(4)
No records
226	Wu E.B., Brilakis E.S., Mashayekhi K., Tsuchikane E., Alaswad K., Araya M., Avran A., Azzalini L., Babunashvili A.M., Bayani B., Behnes M., Bhindi R., Boudou N., Boukhris M., Bozinovic N.Z., Bryniarski L., Bufe A., Buller C.E., Burke M.N., Buttner A., Cardoso P., Carlino M., Chen J.-Y., Christiansen E.H., Colombo A., Croce K., de los Santos F.D., de Martini T., Dens J., di Mario C., Dou K., Egred M., Elbarouni B., ElGuindy A.M., Escaned J., Furkalo S., Gagnor A., Galassi A.R., Garbo R., Gasparini G., Ge J., Ge L., Goel P.K., Goktekin O., Gonzalo N., Grancini L., Hall A., Hanna Quesada F.L., Hanratty C., Harb S., Harding S.A., Hatem R., Henriques J.P.S., Hildick-Smith D., Hill J.M., Hoye A., Jaber W., Jaffer F.A., Jang Y., Jussila R., Kalnins A., Kalyanasundaram A., Kandzari D.E., Kao H.-L., Karmpaliotis D., Kassem H.H., Khatri J., Knaapen P., Kornowski R., Krestyaninov O., Kumar A.V.G., Lamelas P.M., Lee S.-W., Lefevre T., Leung R., Li Y., Li Y., Lim S.-T., Lo S., Lombardi W., Maran A., McEntegart M., Moses J., Munawar M., Navarro A., Ngo H.M., Nicholson W., Oksnes A., Olivecrona G.K., Padilla L., Patel M., Pershad A., Postu M., Qian J., Quadros A., Rafeh N.A., Råmunddal T., Prakasa Rao V.S., Reifart N., Riley R.F., Rinfret S., Saghatelyan M., Sianos G., Smith E., Spaedy A., Spratt J., Stone G., Strange J.W., Tammam K.O., Thompson C.A., Toma A., Tremmel J.A., Trinidad R.S., Ungi I., Vo M., Vu V.H., Walsh S., Werner G., Wojcik J., Wollmuth J., Xu B., Yamane M., Ybarra L.F., Yeh R.W., Zhang Q.	9234022900;6701693111;36915264400;7004090536;6505946630;36125909000;57191835867;16300760500;6603588183;36112736500;24175917200;57203195611;25644193800;55771360100;56614042000;6701830118;7003940019;7005611133;7402868324;57226702911;56498701800;6603766324;57256056100;57226703370;35354455800;6602373657;24471503100;56582201200;57226039988;7101723312;14059806100;13006459000;24340486800;56631052000;56517095000;6602714721;57208183057;36147189600;6506467751;12775032600;57208557113;55429799000;7101942299;7003402250;24484668300;6602258753;57204447163;57217993296;55813173400;57207486260;7202447753;35721997800;56241710300;8089365300;55652210200;55167799300;8847051400;6603908821;55429942500;8588323800;56680930800;15044594400;7003465312;7201431849;35461263500;55674926900;6603058431;6602836006;16947378300;57200584086;57211377689;55958468700;17233718400;13608617100;56844820300;57226704048;26643413600;57226702255;7401542169;57190795527;57189630940;12787521600;55607974600;16747447600;57203315496;57210443231;24535139700;57208573295;8656313100;8650273000;54405153100;6602083383;24171461000;57192202763;13606417300;35271217100;12040029100;57210446588;8088718100;36097159500;6603444680;24482001100;7003691774;7408612732;6507039495;35597798500;7202761439;7006073350;36176507300;7404238092;55856263600;8295981700;57226702476;6602555341;55216966500;57210443999;7202682240;7202099557;7102180606;9736657700;57226703826;36783291300;25655495600;14010649400;57276606800;	Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review	2021	Journal of the American College of Cardiology	78	8		840	853	6	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112399031&doi=10.1016%2fj.jacc.2021.05.055&partnerID=40&md5=a738f413bb74b59eaab8546d85756a5a	Prince of Wales Hospital, Chinese University Hong Kong, Hong Kong; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, United States; Department of Cardiology and Angiology, II University Heart Center Freiburg, Bad Krozingen, Germany; Toyohashi Heart CenterAichi, Japan; Edith and Benson Ford Heart and Vascular Institute, Henry Ford Hospital, Henry Ford Health System, Wayne State University, Detroit, MI, United States; Clinica Alemana, Hospital Militar de Santiago, Santiago, Chile; Pasteur Clinic Essey-lès-Nancy, Essey-lès-Nancy, France; Division of Cardiology, VCU Health Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States; Center of Endosurgery, Moscow, Russian Federation; Cardiology Department, Mehr Hospital, Mashhad, Iran; First Department of Medicine, University Medical Centre Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany; Royal North Shore Hospital, University of Sydney, Sydney, Australia; Interventional Cardiology, Clinique Saint Augustin, Bordeaux, France; Cardiology Department, Abderrahment Mami Hospital, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia; University Clinical Niš, Niš, Serbia; II Department of Cardiology and Cardiovascular Interventions, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; Heart Center Krefeld, University Witten/Herdecke, Witten, Germany; Teleflex, Markham, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; Santa Maria University Hospital, Lisbon Academic Medical Centre and Centro Cardiovascular da Universidade de Lisboa, Lisbon, Portugal; Interventional Cardiology Unit, Cardio-Thoracic-Vascular Department, IRCCS, San Raffaele Scientific Institute, Milan, Italy; Guangdong General HospitalGuangdong, China; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Cardiology, Humanitas University, Humanitas IRCCS, Rozzano, Milan, Italy; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States; Instituto Nacional de Cardiologia, Ignacio Chávez and Centro Medico ABC, Mexico City, Mexico; Advocate Heart Institute, Downers Grove, IL, United States; Hospital Oost-Limburg, Genk, Belgium; Department of Clinical & Experimental Medicine, University Hospital Careggi, Florence, Italy; Research Center for Coronary Heart Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; Freeman Hospital & Newcastle University, Newcastle upon Tyne, United Kingdom; St. Boniface Hospital & University of Manitoba, Winnipeg, MB, Canada; Department of Cardiology, Aswan Heart Centre, Magdi Yacoub Foundation, Aswan, Egypt; Hospital Clinico San Carlos, IdISSC, Complutense University of Madrid, Madrid, Spain; National Institute of Surgery and Transplantology NAMS, Kiev, Ukraine; Department of Invasive Cardiology, Maria Vittoria Hospital, Turin, Italy; Cardiovascular Medicine Department of PROMISE University of Palermo, Palermo, Italy; Maria Pia Hospital, GVM Care & Research, Turin, Italy; Department of Invasive Cardiology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy; Zhongshan Hospital, Fudan University, Shanghai, China; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India; Memorial Hospital, Istanbul, Turkey; Interventional Cardiology, Hospital Clinico San Carlos, IdISSC, Universidad Complutense, Madrid, Spain; Centro Cardiologico Monzino, IRCCS, Milan, Italy; Eastern Health/Memorial University of Newfoundland, St. John's, NF, Canada; “Clinica Comfamiliar,”, Pereira, Colombia; Belfast Health and Social Care Trust, Belfast, United Kingdom; Medical University of Graz, University Heart Center, Graz, Austria; Wellington Hospital, Capital and Coast District Health Board, Wellington, New Zealand; Hôpital du Sacré-Coeur de Montréal Université de Montréal, Montréal, Québec, Canada; University of Amsterdam, Amsterdam, Netherlands; Sussex Cardiac Centre, Brighton, UK, United Kingdom; King's College Hospital, London, UK, United Kingdom; Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK, United Kingdom; Emory University, Atlanta, GA, United States; Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Interventional Cardiology, Helsinki Heart Hospital, Helsinki, Finland; Clinic of Cardiovascular Diseases, Riga East Clinical University Hospital, Riga, Latvia; Promed Hospital, Chennai, India; Piedmont Heart Institute and Cardiovascular Services, Atlanta, GA, United States; Department of Internal Medicine, Cardiology Division, Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan; Columbia University, New York, NY, United States; Kasr Alainy Medical School, Cairo University, Cairo, Egypt, and Fujairah Hospital, Ministry of Health, Fujairah, United Arab Emirates; Cleveland Clinic, Cleveland, OH, United States; Heart Center of the Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Cardiology, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Meshalkin Novosibirsk Research Institute, Novosibirsk, Russian Federation; Department of Cardiology, Dr. L.H. Hiranandani Hospital, Mumbai, India; Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina, and Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Institut Cardiovasculaire Paris Sud, Hôpital Prive Jacques Cartier, Massy, France; C.K. Hui Heart Centre, Royal Alexandra Hospital, Edmonton, AB, Canada; Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin, China; National Heart Centre of Singapore, Singapore; Department of Cardiology, Liverpool Hospital and The University of New South Wales, Sydney, Australia; University of Washington, Seattle, WA, United States; Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC, United States; Golden Jubilee National Hospital, Glasgow, United Kingdom; NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY, United States; Binawaluya Cardiac Center and Department of Cardiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, and Department of Cardiology, Faculty of Medicine, Universitas Gadjahmada, Yogyakarta, Indonesia; Hospital de los Valles, Hospital de Especialidades Eugenio Espejo, Universidad San Francisco de Quito, Quito, Ecuador; Choray University Hospital, Hochiminh City, Vietnam, Viet Nam; Emory Healthcare, Atlanta, GA, United States; Heart Department, Haukeland University Hospital, Bergen, Norway; Department of Cardiology SUS-Lund, Lund University, Lund, Sweden; Department of Interventional Cardiology and Endovascular Therapeutics, ICBA, Instituto Cardiovascular, Buenos Aires, Argentina; Division of Cardiovascular Medicine, University of California, San Diego, School of Medicine, San Diego, CA, United States; Chandler Regional Medical Center, Chandler, AZ, United States; Cardiology Department, University of Medicine and Pharmacy “Carol Davila,” Institute of Cardiovascular Diseases “Prof Dr C.C. Iliescu,”, Bucharest, Romania; Beijing Fuwai Hospital, Beijing, China; Interventional Cardiology Division and Post Graduate Course of Cardiology, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil; St. George Hospital University Medical Center, Beirut, Lebanon, and North Oaks Healthcare System, Hammond, LA, United States; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Care Hospitals, Hyderabad, India; Department of Cardiology, Main Taunus Heart Institute, Bad Soden, Germany; The Christ Hospital Health Network, Cincinnati, OH, United States; McGill University Health Centre, Montréal, Québec, Canada; Nork Marash MC, Erebouni MC, Yerevan, Armenia; AHEPA University Hospital, Thessaloniki, Greece; Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, London, UK, United Kingdom; Boone Hospital Center, Columbia, MO, United States; St. George's University Hospital NHS Foundation Trust, London, UK, United Kingdom; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Bristol Royal Infirmary, University Hospital Bristol NHS Trust, Bristol, UK, United Kingdom; Department at the International Medical Center, Jeddah, Saudi Arabia; NYU Langone Medical Center, New York, NY, United States; Department of Internal Medicine II, Division of Cardiology, Medical University of ViennaVienna, Austria; Stanford University Medical Centre, Stanford, CA, United States; PCI Cardiology Group, Bayamon, PR, United States; University of Szeged, Department of Invasive Cardiology, Szeged, Hungary; Royal Columbian Hospital, Vancouver, BC, Canada; Heart Center University Medical Center, Ho Chi Minh City, Vietnam, Viet Nam; Medizinische Klinik I Klinikum Darmstadt, Darmstadt, Germany; Hospital of Invasive Cardiology IKARDIA, Nałęczów/Lublin, Poland; Providence Heart and Vascular Institute, Portland, OR, United States; Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; Saitima St. Luke's International Hospital, Tokyo, Japan; London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada; Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States; Shanghai East Hospital, Tongji University, Shanghai, China	Wu, E.B., Prince of Wales Hospital, Chinese University Hong Kong, Hong Kong; Brilakis, E.S., Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, United States; Mashayekhi, K., Department of Cardiology and Angiology, II University Heart Center Freiburg, Bad Krozingen, Germany; Tsuchikane, E., Toyohashi Heart CenterAichi, Japan; Alaswad, K., Edith and Benson Ford Heart and Vascular Institute, Henry Ford Hospital, Henry Ford Health System, Wayne State University, Detroit, MI, United States; Araya, M., Clinica Alemana, Hospital Militar de Santiago, Santiago, Chile; Avran, A., Pasteur Clinic Essey-lès-Nancy, Essey-lès-Nancy, France; Azzalini, L., Division of Cardiology, VCU Health Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States; Babunashvili, A.M., Center of Endosurgery, Moscow, Russian Federation; Bayani, B., Cardiology Department, Mehr Hospital, Mashhad, Iran; Behnes, M., First Department of Medicine, University Medical Centre Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, Heidelberg, Germany; Bhindi, R., Royal North Shore Hospital, University of Sydney, Sydney, Australia; Boudou, N., Interventional Cardiology, Clinique Saint Augustin, Bordeaux, France; Boukhris, M., Cardiology Department, Abderrahment Mami Hospital, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia; Bozinovic, N.Z., University Clinical Niš, Niš, Serbia; Bryniarski, L., II Department of Cardiology and Cardiovascular Interventions, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; Bufe, A., Heart Center Krefeld, University Witten/Herdecke, Witten, Germany; Buller, C.E., Teleflex, Markham, ON, Canada, St. Michael's Hospital, Toronto, ON, Canada; Burke, M.N., Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, United States; Buttner, A., St. Michael's Hospital, Toronto, ON, Canada; Cardoso, P., Santa Maria University Hospital, Lisbon Academic Medical Centre and Centro Cardiovascular da Universidade de Lisboa, Lisbon, Portugal; Carlino, M., Interventional Cardiology Unit, Cardio-Thoracic-Vascular Department, IRCCS, San Raffaele Scientific Institute, Milan, Italy; Chen, J.-Y., Guangdong General HospitalGuangdong, China; Christiansen, E.H., Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Colombo, A., Cardiology, Humanitas University, Humanitas IRCCS, Rozzano, Milan, Italy; Croce, K., Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States; de los Santos, F.D., Instituto Nacional de Cardiologia, Ignacio Chávez and Centro Medico ABC, Mexico City, Mexico; de Martini, T., Advocate Heart Institute, Downers Grove, IL, United States; Dens, J., Hospital Oost-Limburg, Genk, Belgium; di Mario, C., Department of Clinical & Experimental Medicine, University Hospital Careggi, Florence, Italy; Dou, K., Research Center for Coronary Heart Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; Egred, M., Freeman Hospital & Newcastle University, Newcastle upon Tyne, United Kingdom; Elbarouni, B., St. Boniface Hospital & University of Manitoba, Winnipeg, MB, Canada; ElGuindy, A.M., Department of Cardiology, Aswan Heart Centre, Magdi Yacoub Foundation, Aswan, Egypt; Escaned, J., Hospital Clinico San Carlos, IdISSC, Complutense University of Madrid, Madrid, Spain; Furkalo, S., National Institute of Surgery and Transplantology NAMS, Kiev, Ukraine; Gagnor, A., Department of Invasive Cardiology, Maria Vittoria Hospital, Turin, Italy; Galassi, A.R., Cardiovascular Medicine Department of PROMISE University of Palermo, Palermo, Italy; Garbo, R., Maria Pia Hospital, GVM Care & Research, Turin, Italy; Gasparini, G., Department of Invasive Cardiology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy; Ge, J., Zhongshan Hospital, Fudan University, Shanghai, China; Ge, L., Zhongshan Hospital, Fudan University, Shanghai, China; Goel, P.K., Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India; Goktekin, O., Memorial Hospital, Istanbul, Turkey; Gonzalo, N., Interventional Cardiology, Hospital Clinico San Carlos, IdISSC, Universidad Complutense, Madrid, Spain; Grancini, L., Centro Cardiologico Monzino, IRCCS, Milan, Italy; Hall, A., Eastern Health/Memorial University of Newfoundland, St. John's, NF, Canada; Hanna Quesada, F.L., “Clinica Comfamiliar,”, Pereira, Colombia; Hanratty, C., Belfast Health and Social Care Trust, Belfast, United Kingdom; Harb, S., Medical University of Graz, University Heart Center, Graz, Austria; Harding, S.A., Wellington Hospital, Capital and Coast District Health Board, Wellington, New Zealand; Hatem, R., Hôpital du Sacré-Coeur de Montréal Université de Montréal, Montréal, Québec, Canada; Henriques, J.P.S., University of Amsterdam, Amsterdam, Netherlands; Hildick-Smith, D., Sussex Cardiac Centre, Brighton, UK, United Kingdom; Hill, J.M., King's College Hospital, London, UK, United Kingdom; Hoye, A., Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK, United Kingdom; Jaber, W., Emory University, Atlanta, GA, United States; Jaffer, F.A., Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Jang, Y., Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Jussila, R., Interventional Cardiology, Helsinki Heart Hospital, Helsinki, Finland; Kalnins, A., Clinic of Cardiovascular Diseases, Riga East Clinical University Hospital, Riga, Latvia; Kalyanasundaram, A., Promed Hospital, Chennai, India; Kandzari, D.E., Piedmont Heart Institute and Cardiovascular Services, Atlanta, GA, United States; Kao, H.-L., Department of Internal Medicine, Cardiology Division, Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan; Karmpaliotis, D., Columbia University, New York, NY, United States; Kassem, H.H., Kasr Alainy Medical School, Cairo University, Cairo, Egypt, and Fujairah Hospital, Ministry of Health, Fujairah, United Arab Emirates; Khatri, J., Cleveland Clinic, Cleveland, OH, United States; Knaapen, P., Heart Center of the Amsterdam University Medical Centers, Amsterdam, Netherlands; Kornowski, R., Department of Cardiology, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Krestyaninov, O., Meshalkin Novosibirsk Research Institute, Novosibirsk, Russian Federation; Kumar, A.V.G., Department of Cardiology, Dr. L.H. Hiranandani Hospital, Mumbai, India; Lamelas, P.M., Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina, and Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Lee, S.-W., Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Lefevre, T., Institut Cardiovasculaire Paris Sud, Hôpital Prive Jacques Cartier, Massy, France; Leung, R., C.K. Hui Heart Centre, Royal Alexandra Hospital, Edmonton, AB, Canada; Li, Y., Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Li, Y., Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin, China; Lim, S.-T., National Heart Centre of Singapore, Singapore; Lo, S., Department of Cardiology, Liverpool Hospital and The University of New South Wales, Sydney, Australia; Lombardi, W., University of Washington, Seattle, WA, United States; Maran, A., Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC, United States; McEntegart, M., Golden Jubilee National Hospital, Glasgow, United Kingdom; Moses, J., NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY, United States; Munawar, M., Binawaluya Cardiac Center and Department of Cardiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, and Department of Cardiology, Faculty of Medicine, Universitas Gadjahmada, Yogyakarta, Indonesia; Navarro, A., Hospital de los Valles, Hospital de Especialidades Eugenio Espejo, Universidad San Francisco de Quito, Quito, Ecuador; Ngo, H.M., Choray University Hospital, Hochiminh City, Vietnam, Viet Nam; Nicholson, W., Emory Healthcare, Atlanta, GA, United States; Oksnes, A., Heart Department, Haukeland University Hospital, Bergen, Norway; Olivecrona, G.K., Department of Cardiology SUS-Lund, Lund University, Lund, Sweden; Padilla, L., Department of Interventional Cardiology and Endovascular Therapeutics, ICBA, Instituto Cardiovascular, Buenos Aires, Argentina; Patel, M., Division of Cardiovascular Medicine, University of California, San Diego, School of Medicine, San Diego, CA, United States; Pershad, A., Chandler Regional Medical Center, Chandler, AZ, United States; Postu, M., Cardiology Department, University of Medicine and Pharmacy “Carol Davila,” Institute of Cardiovascular Diseases “Prof Dr C.C. Iliescu,”, Bucharest, Romania; Qian, J., Beijing Fuwai Hospital, Beijing, China; Quadros, A., Interventional Cardiology Division and Post Graduate Course of Cardiology, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil; Rafeh, N.A., St. George Hospital University Medical Center, Beirut, Lebanon, and North Oaks Healthcare System, Hammond, LA, United States; Råmunddal, T., Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Prakasa Rao, V.S., Care Hospitals, Hyderabad, India; Reifart, N., Department of Cardiology, Main Taunus Heart Institute, Bad Soden, Germany; Riley, R.F., The Christ Hospital Health Network, Cincinnati, OH, United States; Rinfret, S., McGill University Health Centre, Montréal, Québec, Canada; Saghatelyan, M., Nork Marash MC, Erebouni MC, Yerevan, Armenia; Sianos, G., AHEPA University Hospital, Thessaloniki, Greece; Smith, E., Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, London, UK, United Kingdom; Spaedy, A., Boone Hospital Center, Columbia, MO, United States; Spratt, J., St. George's University Hospital NHS Foundation Trust, London, UK, United Kingdom; Stone, G., The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Strange, J.W., Bristol Royal Infirmary, University Hospital Bristol NHS Trust, Bristol, UK, United Kingdom; Tammam, K.O., Department at the International Medical Center, Jeddah, Saudi Arabia; Thompson, C.A., NYU Langone Medical Center, New York, NY, United States; Toma, A., Department of Internal Medicine II, Division of Cardiology, Medical University of ViennaVienna, Austria; Tremmel, J.A., Stanford University Medical Centre, Stanford, CA, United States; Trinidad, R.S., PCI Cardiology Group, Bayamon, PR, United States; Ungi, I., University of Szeged, Department of Invasive Cardiology, Szeged, Hungary; Vo, M., Royal Columbian Hospital, Vancouver, BC, Canada; Vu, V.H., Heart Center University Medical Center, Ho Chi Minh City, Vietnam, Viet Nam; Walsh, S., Belfast Health and Social Care Trust, Belfast, United Kingdom; Werner, G., Medizinische Klinik I Klinikum Darmstadt, Darmstadt, Germany; Wojcik, J., Hospital of Invasive Cardiology IKARDIA, Nałęczów/Lublin, Poland; Wollmuth, J., Providence Heart and Vascular Institute, Portland, OR, United States; Xu, B., Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; Yamane, M., Saitima St. Luke's International Hospital, Tokyo, Japan; Ybarra, L.F., London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada; Yeh, R.W., Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States; Zhang, Q., Shanghai East Hospital, Tongji University, Shanghai, China	The authors developed a global chronic total occlusion crossing algorithm following 10 steps: 1) dual angiography; 2) careful angiographic review focusing on proximal cap morphology, occlusion segment, distal vessel quality, and collateral circulation; 3) approaching proximal cap ambiguity using intravascular ultrasound, retrograde, and move-the-cap techniques; 4) approaching poor distal vessel quality using the retrograde approach and bifurcation at the distal cap by use of a dual-lumen catheter and intravascular ultrasound; 5) feasibility of retrograde crossing through grafts and septal and epicardial collateral vessels; 6) antegrade wiring strategies; 7) retrograde approach; 8) changing strategy when failing to achieve progress; 9) considering performing an investment procedure if crossing attempts fail; and 10) stopping when reaching high radiation or contrast dose or in case of long procedural time, occurrence of a serious complication, operator and patient fatigue, or lack of expertise or equipment. This algorithm can improve outcomes and expand discussion, research, and collaboration. © 2021 The Authors	chronic total occlusion; global; percutaneous coronary intervention; treatment algorithm	algorithm; coronary angiography; coronary artery occlusion; diagnostic imaging; human; percutaneous coronary intervention; Algorithms; Coronary Angiography; Coronary Occlusion; Humans; Percutaneous Coronary Intervention	Elsevier Inc.	07351097	34412818	Review	Q1	10315	73	View
231	Farhoudian A., Radfar S.R., Ardabili H.M., Rafei P., Ebrahimi M., Zonoozi A.K., De Jong C.A.J., Vahidi M., Yunesian M., Kouimtsidis C., Arunogiri S., Hansen H., Brady K.T., Potenza M.N., Baldacchino A.M., Ekhtiari H., Abagiu A.O., Abouna F.D.N., Ahmed M.H., Al-Ansari B., Al-Khair F.M.A., Almaqbali M.H., Ambekar A., Arya S., Asebikan V.O., Ayasreh M.A., Basu D., Benmebarek Z., Bhad R., Blaise M., Bonnet N., Brasch J., Broers B., Busse A., Butner J.L., Camilleri M., Campello G., Carra G., Celic I., Chalabianloo F., Chaturvedi A., Cherpitel J.J.E.N., Clark K.J., Cyders M.A., de Bernardis E., Deilamizade A., Derry J.E., Dhagudu N.K., Dolezalova P., Dom G., Dunlop A.J., Elhabiby M.M., Elkholy H., Essien N.F., Farah G.I., Ferri M., Floros G.D., Friedman C., Fuderanan C.H., Gerra G., Ghosh A., Gogia M., Grammatikopoulos I.A., Grandinetti P., Guirguis A., Gutnisky D., Haber P.S., Hassani-Abharian P., Hooshyari Z., Ibrahim I.I.M., Ieong H.F.-H., Indradewi R.N., Iskandar S., Isra T.N., Jain S., James S., Javadi S.M.H., Joe K.H., Jokubonis D., Jovanova A.T., Kamal R.M., Kantchelov A.I., Kathiresan P., Katzman G., Kawale P., Kern A.M., Kessler F.H.P., Kim S.-G.S., Kimball A.M., Kljucevic Z., Kurniasanti K.S., Lev R., Lee H.K., Lengvenyte A., Lev-Ran S., Mabelya G.S., Mahi M.A.E., Maphisa J.M., Maremmani I., Masferrer L., Massah O., McCambridge O., McGovern G.G., Min A.K., Moghanibashi-Mansourieh A., Mora-Rios J., Mudalige I.U.K., Mukherjee D., Munira P.M., Myers B., Menon T. N. J., Narasimha V.L., Ndionuka N., Nejatisafa A.-A., Niaz K., Nizami A.T., Nuijens J.H., Orsolini L., Oum V., Oyemade A.A., Palavra I.R., Pant S.B., Paredes J., Peyron E., Quirós R.A., Qurishi R., Rafiq N.U.Z., Raghavendra Rao R., Ratta-Apha W., Raymond K.-L., Reimer J., Renaldo E., Rezapour T., Robertson J.R., Roncero C., Roub F., Rubenstein E.J., Rupp C.I., Saenz E., Salehi M., Samartzis L., Sarubbo L.B., Segrec N., Shah B., Shen H., Shirasaka T., Shoptaw S., Sintango F.M., Sosa V.A., Subata E., Sztycberg N., Taghizadeh F., Wee Teck J.B.T., Tjagvad C., Torrens M., Twala J.M., Vadivel R., Volpicelli J.R., Weijs J., Wintoniw S.M., Wittayanookulluk A., Wojnar M., Yasir S., Yitayih Y., Zhao M., ISAM Global Survey Consortium (ISAM-GSC)	25631625900;36019651400;55658200400;57218199674;57218203004;57218205554;55394697400;57203060812;14622058700;6602323007;55912287400;57221996850;7101818468;7006591634;6603786612;26632924600;55021572500;57221605725;57221411272;56996118200;55549232500;57221411355;35749590300;35463222300;57221410006;57221410448;18833291700;57219202850;55789741800;6603894892;15135243700;57189041459;7003868723;57196510693;56816710600;57221410155;56400851700;7003818736;24176502200;26026739900;54936844000;57358665500;57221410761;6504408224;55604104700;56059025100;57221409824;57203836122;6603422138;12768470700;57219674374;26767656700;55086535500;57191041815;57221411550;8871569800;12768168000;57221411410;57210375852;55578764500;36833820900;57205763778;27367905800;55487378900;55496109900;57221411047;7004422180;54892046900;36607951600;57216708013;57193806115;57221410095;37004580200;57221604184;57207211289;57216621884;57207842636;15062725000;57188646762;57221411023;36996943600;24468101500;57023935300;57221410517;55928375400;55031071400;57202970264;57221410531;35420584800;57203155640;57209262171;8913859800;8600274900;57189340754;23019092700;57221410613;57223919852;57200792839;7003948428;6507438528;57044778200;56527137000;57221410507;57221411329;56059054800;6506077151;57214574855;57197364393;57221410358;7202684194;57200567557;56272241600;57221410263;55666521300;57194102646;12144358600;7004198198;55376767200;57217227990;16234058300;57225265059;36114863900;57221411223;57205355338;57221409971;55735687800;57221410341;57358663600;35604346900;56783754400;56000939600;57221410809;56968163500;57205640157;7003524112;57191926633;57221411128;7006106435;26656074800;57226311750;36633076300;57221409908;24476669600;57219874143;57216762422;7005625709;7003465287;57221409902;57221409982;56616079200;57221410011;55802145800;57221409677;57188537200;7006681890;57221411350;57219874702;57209053124;57221410085;57221410695;55151590700;6701757799;57221410275;57204013732;55185317400;	A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic	2021	Frontiers in Psychiatry	12		646206			6	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113236018&doi=10.3389%2ffpsyt.2021.646206&partnerID=40&md5=583fc4953970f4d964584bcd9a7d5b02	Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran; Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States; Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Behavioral Science Institute, Radboud University, Nijmegen, Netherlands; School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Surrey and Borders Partnership National Health Service Foundation Trust, Leatherhead, United Kingdom; Turning Point, Eastern Health, Box Hill, VIC, Australia; Departments of Anthropology and Psychiatry, New York University, New York, NY, United States; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States; Yale School of Medicine, Connecticut Council on Problem Gambling and Connecticut Mental Health Center, New Haven, CT, United States; Division of Population and Behavior Sciences, Medical School, University of St Andrews, St Andrews, United Kingdom; Laureate Institute for Brain Research, Tulsa, OK, United States; National Institute for Infectious Diseases, Prof. Dr. Matei Bals-Arena OMT Department, Romania; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon; Alamal psychiatric hospital, Dubai, United Arab Emirates; Sydney Medical School, University of SydneyNSW, Australia; Al Ahliyya Amman University, Amman, Jordan; Ministry of Health, Muscat, Oman; Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; State Drug Dependence Treatment Centre, Institute of Mental Health, Pt BDS University of Health Sciences, India; Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria; Addiction Medicine Clinic, Jordan; Drug De-addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Addiction Medicine Clinic, Mila, Algeria; Centre medical Marmottan, France; Réseau de Prévention des Addictions (RESPADD), France; Department of Psychiatry and Behavioural Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Geneva University Hospitals, Switzerland; United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; CUNY School of Medicine, New York, United States; Agenzija Sedqa, Malta; Department of Medicine and Surgery, University Milan-Bicocca, Italy; University Psychiatric Hospital Vrapce-Zagreb, Croatia; Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; Addiction Medicine Clinic, Mexico; Addiction Crisis Solutions, United States; Department of Psychology, Indiana University Purdue University-Indianapolis, United States; SerT Lentini, ASP Siracusa, Italy; Rebirth Charity Society NGO, Tehran, Iran; Serenity Vista Addiction Treatment Center, Panama; Department of Psychiatry, ESIC Medical College, Hyderabad, Telangana, India; National Institute of Mental Health, Czech Republic; Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Belgium; Drug & Alcohol Clinical Services, Hunter New England Local Health District, Australia; Ain Shams University, Cairo, Egypt; Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Centre for Research and Information on Substance Abuse, Nigeria; Addiction Medicine Clinic, Syrian Arab Republic; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Italy; Department of Psychiatry, Aristotle University of Thessaloniki, Greece; Brown University and Lifespan Health System, Providence, RI, United States; Fuderanan Mental Health Clinic, Philippines; Drug De-addiction & Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Georgian Harm Reduction Network, Georgia; Organization Against Drugs, Primary Care Health Center, Veria, Greece; Addictions Services (Ser.D.), Department of Territorial Services, ASL Teramo, Italy; Swansea University Medical School, Institute of Life Sciences 2, Singleton CampusSA2 8PP, United Kingdom; Universidad de Buenos Aires, Argentina; University of Sydney, Australia; Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran; Tehran University of Medical Sciences, Tehran, Iran; Department of Anesthesiology, Yale University, United States; Drugs Rehabilitation Center, National Narcotics Board of Indonesia, Indonesia; Department of Psychiatry, Universitas Padjadjaran, Bandung, West Java, Indonesia; National Institute of Education, Sri Lanka; Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India; Univeristi Malaysia Sabah, Malaysia; Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; National Center for Mental Health of Korea, South Korea; Republican Center for Addictive Disorders, Lithuania; Addiction Medicine Clinic, North Macedonia; Naufar Institute, Doha, Qatar; The Kantchelov Clinic, Sofia, Bulgaria; Mount Sinai Medical Center, New York, United States; African Institute for Development Policy, Malawi; Sobriety Centers of New Hampshire, United States; Federal University of Rio Grande do Sul, Brazil; Pusan National University Yangsan Hospital, Department of Neuropsychiatry, Yangsan, South Korea; Chatham House, United States; Institute for Public Health of Split-Dalmatia County, Croatia; Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Indonesia; Scripps Mercy Hospital, San Diego, United States; Department of Psychiatry, The Catholic University of Korea, Seoul, South Korea; Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania; Israel Center on Addiction, Netanya, Israel; Community Health Work, Tanzania; Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan; University of Botswana, Botswana; V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy; CAS Girona, Department of Psychology, University of Girona, Spain; Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Community addiction team, Southern Health and Social Care Trust, United Kingdom; Priority Medical Clinic, Dublin, Ireland; Save the Children International Organization, Burma; Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, United States; Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defence University, Sri Lanka; Centre for Addiction Medicine, NIMHANS, Bangalore, India; Kleopatra Kodric, Irena Nisic, Slovenia; Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa; NIMHANS, Bangalore, India; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, India; Federal Neuropsychiatric Hospital, Calabar, Nigeria; Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran; Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan; Brijder Addiction Care, Zaandam, Netherlands; Department of Clinical Neurosciences/DIMSC, School of Medicine, Polytechnic University of Marche, Ancona, Italy; Koh Kong Provincial Hospital, Cambodia; Kaiser Permanente, United States; Psychiatric hospital Sveti Ivan, Zagreb, Croatia; Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Nepal; Universidad de El Salvador, El Salvador; AddiPsy, Lyon, France; Addiction Medicine Clinic, Costa Rica; Novadic-Kentron Addiction Care Network, Vught, Netherlands; Phoenix Foundation for Research and Development, Pakistan; Barwon Health, Geelong, Australia; Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; University of the Sunshine Coast (USC)QLD, Australia; Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drugs Rehabilitation Center, National Narcotics Board of Indonesia; Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran; Usher Institute, University of Edinburgh, United Kingdom; Psychiatry Service, University of Salamanca Health Care Complex, Salamanca, Spain; PGIMER, Chandigarh, India; Street Health Centre, Canada; Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Austria; Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Medical School, University of Cyprus, Cyprus; Clínica Psiquiátrica de la Facultad de Medicina, Uruguay; Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia; Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal; Department of Psychiatry, Second Xiangya Hospital, Central South University, China; Department of Psychiatry, Teine Keijinkai Medical Center, Japan; David Geffen School of Medicine at UCLA, Department of Family Medicine, United States; Health Professions Councils of Namibia, Namibia; Addiction Medicine Clinic, Uruguay; Asociasion Programa Andres Argentina, Argentina; Mazandaran University of Medical Sciences, Mazandaran, Iran; MRC/CSO SPHSU, University of Glasgow, United Kingdom; Gladsaxe Substance Use Disorder Treatment Centre, Denmark; Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research, Barcelona, Spain; NACADA, Kenya; Waikato District Health Board (WDHB, Hamilton, New Zealand; Institute of Addiction Medicine, United States; Jellinek, Amsterdam, Netherlands; Addictions Foundation of Manitoba, Canada; Thanyarak Chiangmai Hospital, Thailand; Medical University of Warsaw, Warsaw, Poland; Jimma University, Ethiopia; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China	Farhoudian, A., Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Radfar, S.R., Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran, Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States; Ardabili, H.M., Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Rafei, P., Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Ebrahimi, M., Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Zonoozi, A.K., Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; De Jong, C.A.J., Behavioral Science Institute, Radboud University, Nijmegen, Netherlands; Vahidi, M., Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Yunesian, M., School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Kouimtsidis, C., Surrey and Borders Partnership National Health Service Foundation Trust, Leatherhead, United Kingdom; Arunogiri, S., Turning Point, Eastern Health, Box Hill, VIC, Australia; Hansen, H., Departments of Anthropology and Psychiatry, New York University, New York, NY, United States; Brady, K.T., Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States; Potenza, M.N., Yale School of Medicine, Connecticut Council on Problem Gambling and Connecticut Mental Health Center, New Haven, CT, United States; Baldacchino, A.M., Division of Population and Behavior Sciences, Medical School, University of St Andrews, St Andrews, United Kingdom; Ekhtiari, H., Laureate Institute for Brain Research, Tulsa, OK, United States; Abagiu, A.O., National Institute for Infectious Diseases, Prof. Dr. Matei Bals-Arena OMT Department, Romania; Abouna, F.D.N., Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon; Ahmed, M.H., Alamal psychiatric hospital, Dubai, United Arab Emirates; Al-Ansari, B., Sydney Medical School, University of SydneyNSW, Australia; Al-Khair, F.M.A., Al Ahliyya Amman University, Amman, Jordan; Almaqbali, M.H., Ministry of Health, Muscat, Oman; Ambekar, A., Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Arya, S., State Drug Dependence Treatment Centre, Institute of Mental Health, Pt BDS University of Health Sciences, India; Asebikan, V.O., Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria; Ayasreh, M.A., Addiction Medicine Clinic, Jordan; Basu, D., Drug De-addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Benmebarek, Z., Addiction Medicine Clinic, Mila, Algeria; Bhad, R., Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Blaise, M., Centre medical Marmottan, France; Bonnet, N., Réseau de Prévention des Addictions (RESPADD), France; Brasch, J., Department of Psychiatry and Behavioural Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Broers, B., Geneva University Hospitals, Switzerland; Busse, A., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Butner, J.L., CUNY School of Medicine, New York, United States; Camilleri, M., Agenzija Sedqa, Malta; Campello, G., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Carra, G., Department of Medicine and Surgery, University Milan-Bicocca, Italy; Celic, I., University Psychiatric Hospital Vrapce-Zagreb, Croatia; Chalabianloo, F., Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Chaturvedi, A., Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; Cherpitel, J.J.E.N., Addiction Medicine Clinic, Mexico; Clark, K.J., Addiction Crisis Solutions, United States; Cyders, M.A., Department of Psychology, Indiana University Purdue University-Indianapolis, United States; de Bernardis, E., SerT Lentini, ASP Siracusa, Italy; Deilamizade, A., Rebirth Charity Society NGO, Tehran, Iran; Derry, J.E., Serenity Vista Addiction Treatment Center, Panama; Dhagudu, N.K., Department of Psychiatry, ESIC Medical College, Hyderabad, Telangana, India; Dolezalova, P., National Institute of Mental Health, Czech Republic; Dom, G., Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Belgium; Dunlop, A.J., Drug & Alcohol Clinical Services, Hunter New England Local Health District, Australia; Elhabiby, M.M., Ain Shams University, Cairo, Egypt; Elkholy, H., Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Essien, N.F., Centre for Research and Information on Substance Abuse, Nigeria; Farah, G.I., Addiction Medicine Clinic, Syrian Arab Republic; Ferri, M., European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Italy; Floros, G.D., Department of Psychiatry, Aristotle University of Thessaloniki, Greece; Friedman, C., Brown University and Lifespan Health System, Providence, RI, United States; Fuderanan, C.H., Fuderanan Mental Health Clinic, Philippines; Gerra, G., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Ghosh, A., Drug De-addiction & Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Gogia, M., Georgian Harm Reduction Network, Georgia; Grammatikopoulos, I.A., Organization Against Drugs, Primary Care Health Center, Veria, Greece; Grandinetti, P., Addictions Services (Ser.D.), Department of Territorial Services, ASL Teramo, Italy; Guirguis, A., Swansea University Medical School, Institute of Life Sciences 2, Singleton CampusSA2 8PP, United Kingdom; Gutnisky, D., Universidad de Buenos Aires, Argentina; Haber, P.S., University of Sydney, Australia; Hassani-Abharian, P., Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran; Hooshyari, Z., Tehran University of Medical Sciences, Tehran, Iran; Ibrahim, I.I.M., Ain Shams University, Cairo, Egypt; Ieong, H.F.-H., Department of Anesthesiology, Yale University, United States; Indradewi, R.N., Drugs Rehabilitation Center, National Narcotics Board of Indonesia, Indonesia; Iskandar, S., Department of Psychiatry, Universitas Padjadjaran, Bandung, West Java, Indonesia; Isra, T.N., National Institute of Education, Sri Lanka; Jain, S., Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India; James, S., Univeristi Malaysia Sabah, Malaysia; Javadi, S.M.H., Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; Joe, K.H., National Center for Mental Health of Korea, South Korea; Jokubonis, D., Republican Center for Addictive Disorders, Lithuania; Jovanova, A.T., Addiction Medicine Clinic, North Macedonia; Kamal, R.M., Naufar Institute, Doha, Qatar; Kantchelov, A.I., The Kantchelov Clinic, Sofia, Bulgaria; Kathiresan, P., Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Katzman, G., Mount Sinai Medical Center, New York, United States; Kawale, P., African Institute for Development Policy, Malawi; Kern, A.M., Sobriety Centers of New Hampshire, United States; Kessler, F.H.P., Federal University of Rio Grande do Sul, Brazil; Kim, S.-G.S., Pusan National University Yangsan Hospital, Department of Neuropsychiatry, Yangsan, South Korea; Kimball, A.M., Chatham House, United States; Kljucevic, Z., Institute for Public Health of Split-Dalmatia County, Croatia; Kurniasanti, K.S., Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Indonesia; Lev, R., Scripps Mercy Hospital, San Diego, United States; Lee, H.K., Department of Psychiatry, The Catholic University of Korea, Seoul, South Korea; Lengvenyte, A., Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania; Lev-Ran, S., Israel Center on Addiction, Netanya, Israel; Mabelya, G.S., Community Health Work, Tanzania; Mahi, M.A.E., Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan; Maphisa, J.M., University of Botswana, Botswana; Maremmani, I., V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy; Masferrer, L., CAS Girona, Department of Psychology, University of Girona, Spain; Massah, O., Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; McCambridge, O., Community addiction team, Southern Health and Social Care Trust, United Kingdom; McGovern, G.G., Priority Medical Clinic, Dublin, Ireland; Min, A.K., Save the Children International Organization, Burma; Moghanibashi-Mansourieh, A., Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; Mora-Rios, J., Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, United States; Mudalige, I.U.K., Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defence University, Sri Lanka; Mukherjee, D., Centre for Addiction Medicine, NIMHANS, Bangalore, India; Munira, P.M., Kleopatra Kodric, Irena Nisic, Slovenia; Myers, B., Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa; Menon T. N., J., NIMHANS, Bangalore, India; Narasimha, V.L., Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, India; Ndionuka, N., Federal Neuropsychiatric Hospital, Calabar, Nigeria; Nejatisafa, A.-A., Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran; Niaz, K., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Nizami, A.T., Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan; Nuijens, J.H., Brijder Addiction Care, Zaandam, Netherlands; Orsolini, L., Department of Clinical Neurosciences/DIMSC, School of Medicine, Polytechnic University of Marche, Ancona, Italy; Oum, V., Koh Kong Provincial Hospital, Cambodia; Oyemade, A.A., Kaiser Permanente, United States; Palavra, I.R., Psychiatric hospital Sveti Ivan, Zagreb, Croatia; Pant, S.B., Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Nepal; Paredes, J., Universidad de El Salvador, El Salvador; Peyron, E., AddiPsy, Lyon, France; Quirós, R.A., Addiction Medicine Clinic, Costa Rica; Qurishi, R., Novadic-Kentron Addiction Care Network, Vught, Netherlands; Rafiq, N.U.Z., Phoenix Foundation for Research and Development, Pakistan; Raghavendra Rao, R., Barwon Health, Geelong, Australia; Ratta-Apha, W., Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Raymond, K.-L., University of the Sunshine Coast (USC)QLD, Australia; Reimer, J., Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Renaldo, E., Drugs Rehabilitation Center, National Narcotics Board of Indonesia; Rezapour, T., Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran; Robertson, J.R., Usher Institute, University of Edinburgh, United Kingdom; Roncero, C., Psychiatry Service, University of Salamanca Health Care Complex, Salamanca, Spain; Roub, F., PGIMER, Chandigarh, India; Rubenstein, E.J., Street Health Centre, Canada; Rupp, C.I., Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Austria; Saenz, E., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Salehi, M., Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Samartzis, L., Medical School, University of Cyprus, Cyprus; Sarubbo, L.B., Clínica Psiquiátrica de la Facultad de Medicina, Uruguay; Segrec, N., Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia; Shah, B., Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal; Shen, H., Department of Psychiatry, Second Xiangya Hospital, Central South University, China; Shirasaka, T., Department of Psychiatry, Teine Keijinkai Medical Center, Japan; Shoptaw, S., David Geffen School of Medicine at UCLA, Department of Family Medicine, United States; Sintango, F.M., Health Professions Councils of Namibia, Namibia; Sosa, V.A., Addiction Medicine Clinic, Uruguay; Subata, E., Republican Center for Addictive Disorders, Lithuania; Sztycberg, N., Asociasion Programa Andres Argentina, Argentina; Taghizadeh, F., Mazandaran University of Medical Sciences, Mazandaran, Iran; Wee Teck, J.B.T., MRC/CSO SPHSU, University of Glasgow, United Kingdom; Tjagvad, C., Gladsaxe Substance Use Disorder Treatment Centre, Denmark; Torrens, M., Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research, Barcelona, Spain; Twala, J.M., NACADA, Kenya; Vadivel, R., Waikato District Health Board (WDHB, Hamilton, New Zealand; Volpicelli, J.R., Institute of Addiction Medicine, United States; Weijs, J., Jellinek, Amsterdam, Netherlands; Wintoniw, S.M., Addictions Foundation of Manitoba, Canada; Wittayanookulluk, A., Thanyarak Chiangmai Hospital, Thailand; Wojnar, M., Medical University of Warsaw, Warsaw, Poland; Yasir, S., Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan; Yitayih, Y., Jimma University, Ethiopia; Zhao, M., Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China; ISAM Global Survey Consortium (ISAM-GSC)	Background and Aims: COVID-19 has infected more than 77 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing, and “lockdown” measures have affected drug and alcohol supply chains and subsequently their availability, price, and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic. Design: Cross-sectional survey. Setting: Worldwide. Participants: Starting on April 4, 2020 during a 5-week period, the survey received 185 responses from 77 countries. Measurements: To assess addiction medicine professionals' perceived changes in drug and alcohol supply, price, use pattern, and related complications during the COVID-19 pandemic. Findings: Participants reported (among who answered “decreased” or “increased”) a decrease in drug supply (69.0%) and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported, while the use of amphetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall. Conclusions: The global report on changes in the availability, use patterns, and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to people with SUD. © Copyright © 2021 Farhoudian, Radfar, Mohaddes Ardabili, Rafei, Ebrahimi, Khojasteh Zonoozi, De Jong, Vahidi, Yunesian, Kouimtsidis, Arunogiri, Hansen, Brady, ISAM Global Survey Consortium (ISAM-GSC), Potenza, Baldacchino and Ekhtiari.	addiction; behavioral addiction; COVID-19; global survey; illicit drug market; substance use disorder	alcohol; cannabis; illicit drug; addiction medicine; adult; Article; coronavirus disease 2019; drug bioavailability; drug industry; female; gambling; health care personnel; health service; human; male; pandemic; pharmacist; prescription; questionnaire; substance use	Frontiers Media S.A.	16640640		Article	Q1	1363	2668	View
397	Siste K., Hanafi E., Sen L.T., Murtani B.J., Christian H., Limawan A.P., Siswidiani L.P., Adrian	55644113100;56737010600;57219034101;57216652176;57209266195;57202712511;57219029296;57216932703;	Implications of COVID-19 and Lockdown on Internet Addiction Among Adolescents: Data From a Developing Country	2021	Frontiers in Psychiatry	12		665675			6	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107077623&doi=10.3389%2ffpsyt.2021.665675&partnerID=40&md5=19567c64b9f1c1b25ae702d165f6737d	Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia	Siste, K., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Hanafi, E., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Sen, L.T., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Murtani, B.J., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Christian, H., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Limawan, A.P., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Siswidiani, L.P., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Adrian, Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia	Introduction: Physical distancing policy during coronavirus disease 2019 (COVID-19) pandemic requires adolescents to spend most of their time at home, thus increasing Internet use duration. Limited social interaction with their peers may lead to loneliness and an increased risk of mental health among adolescents. This study aimed to assess the prevalence of Internet addiction (IA) among adolescents and analyze the influence of psychosocial factors toward the heightened risk of IA during the COVID-19 pandemic. Methods: An online survey comprising sociodemographic questionnaire, Internet Addiction Diagnostic Questionnaire (KDAI), Strengths and Difficulties Questionnaire (SDQ), and Pittsburgh Sleep Quality Index (PSQI) was distributed. Overall, a total of 2,932 adolescents (mean age, 17.38 ± 2.24 years old; female, 78.7%), originating from 33 of 34 provinces in Indonesia, completed the survey. Results: The point prevalence of IA among Indonesian adolescents during the COVID-19 outbreak was 19.3%. Increased Internet use duration, internalization, externalization, low prosocial behavior, and sleep disturbances were found as risk factors of IA, either directly or as mediating variables. Physical distancing, large-scale social restriction (PSBB), and health status were not correlated to IA. Discussion: Physical distancing was not established as a risk of IA. This could be due to other psychological factors such as internalization, externalization, prosocial, and sleep problems that had correlations to IA occurrence among adolescents in the COVID-19 pandemic. Sleep impairment might have resulted from the emotional and behavioral issues and directly contributed to IA development. Conclusion: The present study found the prevalence of IA among Indonesian adolescents to be higher than the adult during the COVID-19 pandemic. Several psychological measures were indicated to increase the risk of IA, while physical distancing did not elevate the risk. Thus, remote schooling is preferable in Indonesia along with proper parental supervision to minimize Internet use for entertainment purposes. © Copyright © 2021 Siste, Hanafi, Sen, Murtani, Christian, Limawan, Siswidiani and Adrian.	adolescents; coronavirus disease 2019; Indonesia; internet addiction; lockdown; physical distancing; psychopathology; sleep quality	adolescent; adolescent disease; age distribution; Article; behavior disorder; controlled study; coronavirus disease 2019; demography; developing country; emotional disorder; externalization (behavior); female; health status; health survey; human; Indonesia; Indonesian; internalization (behavior); internet addiction; Internet Addiction Diagnostic Questionnaire; major clinical study; male; national lockdown; pandemic; Pittsburgh Sleep Quality Index; prevalence; prosocial behavior; psychological aspect; questionnaire; risk assessment; sex ratio; sleep disorder; social aspect; social distancing; social psychology; strengths and difficulties questionnaire	Frontiers Media S.A.	16640640		Article	Q1	1363	2668	View
597	Pranata R., Yonas E., Vania R., Sidipratomo P., July J.	57201973901;57201987097;57208328436;55674568400;24080082500;	Efficacy and safety of PulseRider for treatment of wide-necked intracranial aneurysm—A systematic review and meta-analysis	2021	Interventional Neuroradiology	27	1		60	67	6	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087679822&doi=10.1177%2f1591019920940521&partnerID=40&md5=03cec8e157ad6f45c39b181ca201f6fb	Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Department of Radiology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Neurosurgery, Medical Faculty, Pelita Harapan University, Tangerang, Indonesia; Neuroscience Centre Siloam Hospital, Tangerang, Indonesia	Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Vania, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Sidipratomo, P., Department of Radiology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; July, J., Department of Neurosurgery, Medical Faculty, Pelita Harapan University, Tangerang, Indonesia, Neuroscience Centre Siloam Hospital, Tangerang, Indonesia	Objective: PulseRider is a novel self-expanding nickel-titanium (nitinol) stent for treatment of wide-necked aneurysms, which is commonly located at the arterial branches in the brain. This systematic review and meta-analysis aims to assess the efficacy and safety of PulseRider for treatment of wide-necked intracranial aneurysm. Method: We performed a systematic literature search on articles that evaluate the efficacy and safety of PulseRider-assisted coiling of the wide-necked aneurysm from several electronic databases. The primary endpoint was adequate occlusion, defined as Raymond-Roy Class I + Raymond-Roy Class II upon immediate angiography and at six-month follow-up. Results: There were a total of 157 subjects from six studies. The rate of adequate occlusion on immediate angiography was 90% (95% CI, 85%–94%) and 91% (95% CI, 85%–96%) at six-month follow-up. Of these, Raymond-Roy Class I can be observed in 48% (95% CI, 41%–56%) of aneurysms immediately after coiling, and 64% (95% CI, 55%–72%) of aneurysms on six-month follow-up. Raymond-Roy Class II was found in 30% (95% CI, 23%–37%) of aneurysms immediately after coiling, and 25% (17–33) after six-month follow-up. Complications occur in 5% (95% CI, 1%–8%) of the patients. There were three intraoperative aneurysm rupture, three thrombus formation, three procedure-related posterior cerebral artery strokes, one vessel dissection, and one delayed device thrombosis. There was no procedure/device-related death. Conclusions: PulseRider-assisted coiling for treatment of patients with wide-necked aneurysm reached 90% adequate occlusion rate that rises up to 91% at sixth month with 5% complication rate. © The Author(s) 2020.	Coiling; endovascular; intracranial aneurysm; PulseRider; wide-necked aneurysm	antithrombocytic agent; adult; aneurysm rupture; angiography; arterial spin labeling; Article; blood clotting; cerebral artery disease; coil embolization; comparative effectiveness; dissection; drug safety; female; human; intracranial aneurysm; magnetic resonance angiography; male; metastasis; nuclear magnetic resonance imaging; occlusion; systematic review; thrombosis	SAGE Publications Inc.	15910199	32635777	Article	Q2	574	8811	View
7(1)
No records
455	Wang G., Tanaka A., Zhao H., Jia J., Ma X., Harada K., Wang F.-S., Wei L., Wang Q., Sun Y., Hong Y., Rao H., Efe C., Lau G., Payawal D., Gani R., Lindor K., Jafri W., Omata M., Sarin S.K.	7407149871;57208572262;57200532284;57218488345;7404550067;57212924064;57216339526;7402950828;55531131800;56402234600;57188750283;8220686600;25122065500;36114075400;7801385732;23495930300;35418813000;23091123700;36043368300;57220191468;	The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis	2021	Hepatology International	15	2		223	257	7	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105607533&doi=10.1007%2fs12072-021-10170-1&partnerID=40&md5=eef4f926d521f19ad391095aa3af27f0	Peking University First Hospital, Beijing, China; Teikyo University School of Medicine, Tokyo, Japan; Beijing Friendship Hospital, Capital Medical University, Beijing, China; Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Department of Human Pathology, Kanazawa University Graduate School of Medicine Kanazawa, Kanazawa, Japan; Fifth Medical Center, Chinese PLA General Hospital, Beijing, China; Beijing Tsinghua Changgung Hospital, Beijing, China; Peking University People’s Hospital, Beijing, China; Department of Gastroenterology, Harran University, Şanlıurfa, Turkey; Humanity and Health Medical Group, Hong Kong; Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines; Department of Internal Medicine, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; College of Health Solutions, Arizona State University, Phoenix, AZ, United States; Aga Khan University, Karachi, Pakistan; Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-City, Yamanashi, Japan; The University of Tokyo, Tokyo, Japan; Institute of Liver and Biliary Sciences, New Delhi, India; Peking University International Hospital, Beijing, China	Wang, G., Peking University First Hospital, Beijing, China, Peking University International Hospital, Beijing, China; Tanaka, A., Teikyo University School of Medicine, Tokyo, Japan; Zhao, H., Peking University First Hospital, Beijing, China, Peking University International Hospital, Beijing, China; Jia, J., Beijing Friendship Hospital, Capital Medical University, Beijing, China; Ma, X., Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Harada, K., Department of Human Pathology, Kanazawa University Graduate School of Medicine Kanazawa, Kanazawa, Japan; Wang, F.-S., Fifth Medical Center, Chinese PLA General Hospital, Beijing, China; Wei, L., Beijing Tsinghua Changgung Hospital, Beijing, China; Wang, Q., Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Sun, Y., Fifth Medical Center, Chinese PLA General Hospital, Beijing, China; Hong, Y., Peking University First Hospital, Beijing, China; Rao, H., Peking University People’s Hospital, Beijing, China; Efe, C., Department of Gastroenterology, Harran University, Şanlıurfa, Turkey; Lau, G., Humanity and Health Medical Group, Hong Kong; Payawal, D., Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines; Gani, R., Department of Internal Medicine, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Lindor, K., College of Health Solutions, Arizona State University, Phoenix, AZ, United States; Jafri, W., Aga Khan University, Karachi, Pakistan; Omata, M., Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-City, Yamanashi, Japan, The University of Tokyo, Tokyo, Japan; Sarin, S.K., Institute of Liver and Biliary Sciences, New Delhi, India	[No abstract available]		6 mercaptopurine derivative; azathioprine; budesonide; corticosteroid; cyclosporine; farnesoid X receptor; infliximab; mycophenolate mofetil; prednisone; rapamycin; tacrolimus; antibody detection; Asia; autoimmune hepatitis; autoimmunity; cataract; chronic liver disease; clinical practice; cytokine production; decompensated liver cirrhosis; diabetes mellitus; disease predisposition; drug efficacy; drug exposure; drug safety; dual energy X ray absorptiometry; environmental factor; gene locus; genetic susceptibility; geographic distribution; human; hypertension; immunoglobulin blood level; immunological tolerance; immunoregulation; incidence; liver biopsy; liver cell carcinoma; liver transplantation; magnetic resonance elastography; nonalcoholic fatty liver; Note; osteoporosis; Pacific islan	Springer	19360533	33942203	Note	Q2	1304	2874	View
76(1)
No records
558	Pranata R., Lim M.A., Yonas E., Vania R., Lukito A.A., Siswanto B.B., Meyer M.	57201973901;57216039756;57201987097;57208328436;57213835420;14422648800;57217373886;	Body mass index and outcome in patients with COVID-19: A dose–response meta-analysis	2021	Diabetes and Metabolism	47	2	101178			76	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089283809&doi=10.1016%2fj.diabet.2020.07.005&partnerID=40&md5=a6503da65fb4a1f9b97a1b42e95385cf	Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia	Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Lim, M.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Vania, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Lukito, A.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia, Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia; Siswanto, B.B., Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Meyer, M., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia	Background: There is mounting evidence related to the association between obesity and severity of COVID-19. However, the direct relationship of the increase in the severe COVID-19 risk factors, with an increase in body mass index (BMI), has not yet been evaluated. Aim: This meta-analysis aims to evaluate the dose–response relationship between body mass index (BMI) and poor outcome in patients with COVID-19. Methods: A systematic literature search was conducted using PubMed, Europe PMC, ProQuest, and the Cochrane Central Database. The primary outcome was composite poor outcome composed of mortality and severity. The secondary outcomes were mortality and severity. Results: A total of 34,390 patients from 12 studies were included in this meta-analysis. The meta-analysis demonstrated that obesity was associated with composite poor outcome (OR 1.73 [1.40, 2.14], P < 0.001; I2: 55.6%), mortality (OR 1.55 [1.16, 2.06], P = 0.003; I2: 74.4%), and severity (OR 1.90 [1.45, 2.48], P < 0.001; I2: 5.2%) in patients with COVID-19. A pooled analysis of highest BMI versus reference BMI indicate that a higher BMI in the patients was associated with composite poor outcome (aOR 3.02 [1.82, 5.00], P < 0.001; I2: 59.8%), mortality (aOR 2.85 [1.17, 6.92], P = 0.002; I2: 79.7%), and severity (aOR 3.08 [1.78, 5.33], P < 0.001; I2: 11.7%). The dose–response meta-analysis showed an increased risk of composite poor outcome by aOR of 1.052 [1.028, 1.077], P < 0.001 for every 5 kg/m2 increase in BMI (Pnon-linearity < 0.001). The curve became steeper with increasing BMI. Conclusion: Dose–response meta-analysis demonstrated that increased BMI was associated with increased poor outcome in patients with COVID-19. © 2020 Elsevier Masson SAS	Body mass index; Coronavirus; Obesity; SARS-CoV-2; Weight	antidiabetic agent; antihypertensive agent; adult; aged; antihypertensive therapy; Article; body mass; clinical outcome; coronavirus disease 2019; diabetes mellitus; disease severity; dose response; female; human; hypertension; male; meta analysis; mortality rate; obesity; risk assessment; systematic review; body mass; complication; middle aged; obesity; risk factor; severity of illness index; therapy; treatment outcome; Aged; Body Mass Index; COVID-19; Female; Humans; Male; Middle Aged; Obesity; Risk Factors; SARS-CoV-2; Severity of Illness Index; Treatment Outcome	Elsevier Masson s.r.l.	12623636	32738402	Article	Q1	1480	2328	View
8(3)
No records
66	Pranata R., Yonas E., Huang I., Lim M.A., Nasution S.A., Kuswardhani R.A.T.	57201973901;57201987097;57208576645;57216039756;57189373134;36863900500;	Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis	2021	European journal of gastroenterology & hepatology	33	1S Suppl 1		e368	e374	8	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107230733&doi=10.1097%2fMEG.0000000000002091&partnerID=40&md5=ea06112f412d95910a1757cc5756c08a	Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Faculty of Medicine, Universitas YARSIJakarta, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Indonesia	Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSIJakarta, Indonesia; Huang, I., Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Lim, M.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Nasution, S.A., Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Kuswardhani, R.A.T., Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Indonesia	BACKGROUND/AIMS: In this meta-analysis, we aimed to evaluate the prognostic value of fibrosis-4 index (FIB-4) in COVID-19. METHODS: We performed a comprehensive literature search of PubMed, Embase, and Scopus databases on 26 November 2020. FIB-4 was calculated by [age (years) × AST (IU/L)]/[platelet count (109/L) × √ALT (U/L)]. A value above cutoff point was considered high and a value below cutoff point was considered low. The main outcome was mortality, the association between high FIB-4 and mortality was reported in odds ratio (OR). Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic OR (DOR), area under the curve (AUC) were generated. RESULTS: There were 963 patients from five studies included in this systematic review and meta-analysis. Meta-analysis showed that high FIB-4 was associated with increased mortality [OR 3.96 (2.16-7.27), P < 0.001; I2: 41.3%]. High FIB-4 was associated mortality with a sensitivity of 0.56 (0.40-0.70), specificity of 0.80 (0.72-0.86), PLR 2.8 (1.8-4.2), NLR 0.55 (0.39-0.78), DOR 5 (2-10), and AUC of 0.77 (0.73-0.81). Fagan's nomogram indicated that for a pre-test probability (mortality) of 30%, a high FIB-4 was associated with 54% post-test probability and a low FIB-4 was associated with 19%, respectively. The funnel-plot analysis was asymmetrical, trim-and-fill analysis by imputation of a study on the left side using linear estimator resulted in an OR of 3.48 (1.97-6.14). Egger's test showed no indication of small-study effects (P = 0.881). CONCLUSION: High FIB-4 was associated with mortality in patients with COVID-19. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.		area under the curve; fibrosis; human; meta analysis; platelet count; Area Under Curve; COVID-19; Fibrosis; Humans; Platelet Count; SARS-CoV-2	NLM (Medline)	14735687	35048648	Article	#N/A	#N/A	#N/A	View
81	Raharja A., Tamara A., Kok L.T.	57192080346;57205305387;57219901696;	Association Between Ethnicity and Severe COVID-19 Disease: a Systematic Review and Meta-analysis	2021	Journal of Racial and Ethnic Health Disparities	8	6		1563	1572	8	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096023866&doi=10.1007%2fs40615-020-00921-5&partnerID=40&md5=139e8ff070e1e792a6383269e01b7342	Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia	Raharja, A., Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; Tamara, A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Kok, L.T., Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom	Objectives: This article evaluates if ethnicity is an independent poor prognostic factor in COVID-19 disease. Methods: MEDLINE, EMBASE, Cochrane, WHO COVID-19 databases from inception to 15/06/2020 and medRxiv. No language restriction. Newcastle-Ottawa Scale (NOS) and GRADE framework were utilised to assess the risk of bias and certainty of evidence. PROSPERO CRD42020188421. Results: Seventy-two articles (59 cohort studies with 17,950,989 participants, 13 ecological studies; 54 US-based, 15 UK-based; 41 peer-reviewed) were included for systematic review and 45 for meta-analyses. Risk of bias was low: median NOS 7 of 9 (interquartile range 6–8). Compared to White ethnicity, unadjusted all-cause mortality was similar in Black (RR: 0.96 [95% CI: 0.83–1.08]) and Asian (RR: 0.99 [0.85–1.16]) but reduced in Hispanic ethnicity (RR: 0.69 [0.57–0.84]). Age- and sex-adjusted risks were significantly elevated for Black (HR: 1.38 [1.09–1.75]) and Asian (HR: 1.42 [1.15–1.75]), but not for Hispanic (RR: 1.14 [0.93–1.40]). Further adjusting for comorbidities attenuated these associations to non-significance: Black (HR: 0.95 [0.72–1.25]); Asian (HR: 1.17 [0.84–1.63]); Hispanic (HR: 0.94 [0.63–1.44]). Subgroup analyses showed a trend towards greater disparity in outcomes for UK ethnic minorities, especially hospitalisation risk. Conclusions: This review could not confirm a certain ethnicity as an independent poor prognostic factor for COVID-19. Racial disparities in COVID-19 outcomes may be partially attributed to higher comorbidity rates in certain ethnicity. © 2020, W. Montague Cobb-NMA Health Institute.	Acute kidney injury; COVID-19; Ethnicity; Hospitalisation; Intubation; Mortality	ethnicity; ethnology; human; meta analysis; patient acuity; prognosis; risk factor; therapy; COVID-19; Ethnicity; Humans; Patient Acuity; Prognosis; Risk Factors	Springer Science and Business Media Deutschland GmbH	21973792	33180278	Review	Q1	644	7820	View
215	Dilogo I.H., Aditianingsih D., Sugiarto A., Burhan E., Damayanti T., Sitompul P.A., Mariana N., Antarianto R.D., Liem I.K., Kispa T., Mujadid F., Novialdi N., Luviah E., Kurniawati T., Lubis A.M.T., Rahmatika D.	56161962800;56312263600;57189612291;36058554600;36058523500;57224505288;57194732286;57190862806;55802927800;56515348000;57204398571;57224555404;56114966200;55213290600;15122639800;57474077600;	Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial	2021	Stem Cells Translational Medicine	10	9		1279	1287	8	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107732762&doi=10.1002%2fsctm.21-0046&partnerID=40&md5=197659d90f645ca5130e69fcf16b7b4d	Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia; Department of Orthopaedic and Traumatology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Anesthesiology and Intensive Care Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Intensive Care Division, Universitas Indonesia Hospital, Depok, Indonesia; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan General Hospital, Jakarta, Indonesia; Directorate of Medical Services, Nursing and Supporting, Sulianti Saroso Infection Disease Hospital, Jakarta, Indonesia; Directorate of Human Resources Development, Education and Operational Sulianti Saroso Infection Disease Hospital, Jakarta, Indonesia; Department of Histology, Universitas Indonesia Fakultas Kedokteran, Jakarta, Indonesia; Department of Anatomy, Universitas Indonesia Fakultas Kedokteran, Jakarta, Indonesia; Installation of Innovation Management and Intellectual Property, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Dilogo, I.H., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia, Department of Orthopaedic and Traumatology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Aditianingsih, D., Department of Anesthesiology and Intensive Care Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Intensive Care Division, Universitas Indonesia Hospital, Depok, Indonesia; Sugiarto, A., Department of Anesthesiology and Intensive Care Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Burhan, E., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan General Hospital, Jakarta, Indonesia; Damayanti, T., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan General Hospital, Jakarta, Indonesia; Sitompul, P.A., Directorate of Medical Services, Nursing and Supporting, Sulianti Saroso Infection Disease Hospital, Jakarta, Indonesia; Mariana, N., Directorate of Human Resources Development, Education and Operational Sulianti Saroso Infection Disease Hospital, Jakarta, Indonesia; Antarianto, R.D., Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia, Department of Histology, Universitas Indonesia Fakultas Kedokteran, Jakarta, Indonesia; Liem, I.K., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia, Department of Anatomy, Universitas Indonesia Fakultas Kedokteran, Jakarta, Indonesia; Kispa, T., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Mujadid, F., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Novialdi, N., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Luviah, E., Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia; Kurniawati, T., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Lubis, A.M.T., Department of Orthopaedic and Traumatology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Installation of Innovation Management and Intellectual Property, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rahmatika, D., Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia	One of the main causes of acute respiratory distress syndrome in coronavirus disease 2019 (COVID-19) is cytokine storm, although the exact cause is still unknown. Umbilical cord mesenchymal stromal cells (UC-MSCs) influence proinflammatory T-helper 2 (Th2) cells to shift to an anti-inflammatory agent. To investigate efficacy of UC-MSC administration as adjuvant therapy in critically ill patients with COVID-19, we conducted a double-blind, multicentered, randomized controlled trial at four COVID-19 referral hospitals in Jakarta, Indonesia. This study included 40 randomly allocated critically ill patients with COVID-19; 20 patients received an intravenous infusion of 1 × 106/kg body weight UC-MSCs in 100 ml saline (0.9%) solution (SS) and 20 patients received 100 ml 0.9% SS as the control group. All patients received standard therapy. The primary outcome was measured by survival rate and/or length of ventilator usage. The secondary outcome was measured by clinical and laboratory improvement, with serious adverse events. Our study showed the survival rate in the UC-MSCs group was 2.5 times higher than that in the control group (P =.047), which is 10 patients and 4 patients in the UC-MSCs and control groups, respectively. In patients with comorbidities, UC-MSC administration increased the survival rate by 4.5 times compared with controls. The length of stay in the intensive care unit and ventilator usage were not statistically significant, and no adverse events were reported. The application of infusion UC-MSCs significantly decreased interleukin 6 in the recovered patients (P =.023). Therefore, application of intravenous UC-MSCs as adjuvant treatment for critically ill patients with COVID-19 increases the survival rate by modulating the immune system toward an anti-inflammatory state. © 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.	adjuvants; cord stem cell transplantation; COVID-19; cytokine release syndrome; immunology; mesenchymal stromal cells	5' nucleotidase; azithromycin; C reactive protein; CD34 antigen; CD4 antigen; CD56 antigen; CD8 antigen; chemokine receptor CXCR3; D dimer; ferritin; fibrinogen; hemoglobin; interleukin 10; interleukin 6; lactic acid; leukemia inhibitory factor; oseltamivir; procalcitonin; Thy 1 membrane glycoprotein; vasculotropin; adjuvant therapy; adult; adult respiratory distress syndrome; Article; artificial ventilation; blood cell count; clinical article; clinical decision making; computer assisted tomography; controlled study; coronavirus disease 2019; critically ill patient; cytokine release syndrome; cytokine storm; double blind procedure; female; flow cytometry; fluid resuscitation; ground glass opacity; hematocrit; Horowitz index; human; hypotension; intensive care unit; length of stay; leukopen	John Wiley and Sons Ltd	21576564	34102020	Article	Q1	1781	1654	View

Publikasi Scopus 926 artikel (Per 14 Maret 2022)